Association of PI3K/AKT/mTOR pathway autophagy- related gene polymorphisms with pulmonary tuberculosis susceptibility in a Chinese population

被引:0
|
作者
He, Juan [1 ,2 ]
Liu, Shengyuan [2 ]
Guo, Xujun [2 ]
Zhang, Fan [2 ]
Fan, Yuzheng [2 ]
Wu, Lijuan [2 ]
Takiff, Howard Eugene [3 ]
Zhao, Yashuang [1 ]
机构
[1] Harbin Med Univ, Sch Publ Hlth, Dept Epidemiol, Harbin, Peoples R China
[2] Shenzhen Nanshan Ctr Chron Dis Control, Dept TB Control & Prevent, Shenzhen, Peoples R China
[3] CMBC, Lab Genet Mol, IVIC, Caracas, Venezuela
关键词
PI3K; AKT; mTOR; Autophagy; Tuberculosis; SNP; Genetic risk score; AKT1;
D O I
10.1590/0037-8682-0104-2023
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: Autophagy can inhibit the survival of intracellular microorganisms including Mycobacterium tuberculosis (Mtb), and the PI3K/AKT/mTOR pathway plays a crucial role. This study investigated the association between PI3K/AKT/mTOR pathway autophagy-related gene polymorphisms and pulmonary tuberculosis (PTB) susceptibility.Methods: KEGG pathway and gene ontology (GO) databases were searched for genes belonging to the PI3K/AKT/mTOR and autophagy pathways. Thirty SNPs in nine genes were identified and tested for their associations with tuberculosis in 130 patients with PTB and 271 controls. We constructed genetic risk scores (GRSs) and divided the participants into 3 subgroups based on their GRSs:0-5, 6-10, and 11-16.Results: This analysis revealed that the AKT1 (rs12432802), RPTOR (rs11654508, rs12602885, rs2090204, rs2589144, and rs2672897), and TSC2 (rs2074969) polymorphisms were significantly associated with PTB risk. A decreasing trend was observed (P trend 0.020), in which a lower GRS was associated with a higher risk of PTB ([6-10] vs. [0-5]: OR (95%CI) 0.590 (0.374-0.931); [11-16] vs. [0-5]: OR (95%CI) 0.381 (0.160-0.906)).Conclusions: Polymorphisms in AKT1, RPTOR, and TSC2 may influence susceptibility to PTB.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway
    Mengqing Ma
    Rui Hu
    Qi Huang
    Jing Li
    Minling Lv
    Jialing Sun
    Xin Zhong
    Jinyu Yi
    Lanfen Peng
    Wenxing Feng
    Wenfeng Ma
    Zhiyi Han
    Wei Zhang
    Xinfeng Sun
    Bolin Zhan
    Xingning Liu
    Xiaozhou Zhou
    Cancer Cell International, 24 (1)
  • [42] The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells
    Chang, Huan
    Li, Xin
    Cai, Qian
    Li, Chunyun
    Tian, Lang
    Chen, Jia
    Xing, Xiaowei
    Gan, Yu
    Ouyang, Wen
    Yang, Zuocheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 (01) : 182 - 192
  • [43] Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization
    Sasore, Temitope
    Reynolds, Alison L.
    Kennedy, Breandan N.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 805 - 811
  • [44] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [45] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [46] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [47] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51
  • [48] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543
  • [49] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
    Sapega T.S.
    Guria G.T.
    Biophysics, 2020, 65 (2) : 259 - 267
  • [50] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737